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Messori and colleagues are to be congratulated on their
interesting report on the Italian observational study of
antithrombin III (AT III) use in intensive care units [1]. Audits
of this sort are difficult and time consuming to conduct.
Observational studies are also difficult to analyse and
interpret because of the heterogeneity of real-life patient
populations, the lack of standardised treatment regimens, the
lack of standardised indications for treatment, and the lack of
predefined endpoints for assessing survival (e.g. 28 day
survival or in-hospital mortality). For these reasons we take
issue with Messori and colleagues over the very strong
conclusion they draw on the basis of their survey. In our
opinion, this nonrandomised observational study is not able
to provide scientific evidence to support the authors’
statements.
Observational study
As pointed out by Pocock and Elbourne, observational
studies have one crucial deficiency: the design is not an
experimental one [2]. Experimental design involves
randomisation, the use of entry criteria, and the rigorous use
of standard definitions of index medical conditions such as
disseminated intravascular coagulation and septic shock.
None of these are to be found in the survey by Messori and
colleagues [1]. In the absence of rigorous experimental
methodology, it is not possible to be sure that the findings of
an observational study are predictive of the results of a
randomised, controlled trial (RCT). The published finding that
observational studies usually agree with RCTs comes from
studies in indications unrelated to sepsis and septic shock
[3,4]. Furthermore, it is a logical fallacy to suggest that
agreement in one direction implies prediction in the other
direction. Observational studies are not scientifically capable
of proving or disproving any hypothesis.
With this in mind, it is interesting to note that one of the main
observations of Messori and colleagues’ survey (n = 56 for
sepsis) is at variance with the results from a very much larger
RCT reported in the same indication by Warren and
colleagues (n = 2341 for sepsis) [5]. Whereas Warren and
colleagues’ RCT found significantly lower mortality in a
prespecified subgroup analysis of AT III-treated patients not
receiving heparin (n = 352) compared with placebo-treated
patients not receiving heparin (n = 346), Messori and
colleagues’ survey observed an increase in mortality in
patients not receiving heparin. This casts serious doubt over
the scientific value of a survey reporting outcomes in a
treatment that was not randomised to patients, with only
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Abstract
Observational studies usually agree with randomised, controlled trials. It is a logical fallacy, however, to
suggest that agreement in one direction implies prediction in the other direction. Observational studies
are not scientifically capable of proving or disproving hypotheses such as the efficacy and safety of the
treatment of severe sepsis with antithrombin. Observational studies are difficult to analyse and interpret
because of the heterogeneity of real-life patient populations, the lack of standardised treatment
regimens, the lack of standardised indications for treatment, and the lack of predefined endpoints.
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56 patients with sepsis treated with AT III. Such a type of
study is not scientifically or statistically capable of proving
causality or supporting statements.
Other crucial weaknesses of Messori and colleagues’ survey
lie in its observational nature and the lack of any
standardisation of definitions or outcomes. Controlled studies
usually indicate the 28 day mortality whereas observational
studies indicate the hospital mortality, which normally is
higher than the 28 day mortality. In addition, hospital mortality
may depend on local factors affecting clinical practice such
as when to discharge patients from hospital, which varies
among countries.
Overview of studies
Messori and colleagues also report the results of a meta-
analysis of four studies of AT III in sepsis [5–8]. Conclusions
are drawn based on confidence intervals calculated for their
meta-analysis. It is probably unwise, however, to place too
much weight on meta-analyses of studies conducted in
critical care settings because the spectacular failure of meta-
analyses to predict the outcomes of subsequent large-scale
RCTs is well known [9–11].
Furthemore, if confidence intervals overlap or P > 0.05, this
does not prove that there is no difference; on the contrary,
there is still a possibility that the observation suffers from a
type II error (failure to detect a true difference due to
inadequate sample size). This is particularly likely to occur
when the number of patients studied is small, as in the phase
II trials on AT III. In this context, it is misleading of Messori
and colleagues to use Figure 1 of their paper to suggest,
with reference to the confidence intervals, that there is no
difference between the studies or that their observational
study has a very similar result to the other studies cited. In
the same way, potentially misleading claims are made about
the subgroup analysis of the effects of coadministered
heparin. In the results section it is suggested, erroneously,
that no differences exist between results on the basis of
P values alone.
Conclusion
Surveys and audits are very important ways of documenting
routine clinical practice and of confirming the implementation
of guidelines based on the results of RCTs. Surveys and
audits are also useful for generating hypotheses, but they are
not a substitute for RCTs when proving or disproving
hypotheses. This is because surveys are not based on an
experimental design. Messori and colleagues have raised
interesting concerns but they have not provided answers to
those concerns.
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